Atrium Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $135.6M
- Price
- $7.93
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.75%
- Volume
- 91.8K
About
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Quick stats
Shares outstanding17.1M
Computed float16.2M
Float / shares95.0%
Cash runway (months)40.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002093101
AI Summary
AI-generated1/11
minorneutralother
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics awarded inducement grants to one newly hired non-executive employee on September 20, 2026: non-qualified stock options covering 13,500 shares with a $8.95 exercise price, plus restricted stock units for 6,750 shares.
The awards were made under the company's 2026 Employment Inducement Incentive Award Plan and approved by the Human Capital Management Committee of the Board, comprised solely of independent directors, consistent with Nasdaq Listing Rule 5635(c)(4). Vesting is standard, with 25% at the one-year anniversary and the remainder in monthly (options) or annual (RSUs) installments.
The grant is routine and immaterial in size, tied to a single hire rather than any strategic shift. The release also recaps that the FDA recently cleared Atrium's IND application for ATR 1072 in PRKAG2 syndrome, with the Corventis Phase 1/2 trial advancing the precision cardiology program into the clinic.